Abstract Library

#4617 Analysis of new immunohistochemical biomarkers in a cohort of pancreatic NETs

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are rare diseases with a 10-year survival rate of only 40-50%. The ATRX, DAXX and ARX, PDX1 expressions in PanNETs were considered poor prognostic factors in some studies, but inconsistent in others.

Conference:

Presenting Author:

Authors: Ciobanu O, Martin S, Herlea V, Vasilescu F, Balaban D,

Keywords: Pancreatic neuroendocrine tumour, ATRX, DAXX, ARX, PDX1,

#4185 Primary hepatic neuroendocrine neoplasms – Clinical characteristics and treatment outcomes of a rare disease

Introduction: Liver involvement in Neuroendocrine Neoplasms (NEN) most commonly encompasses metastases from other organs or from an unknown primary. The current WHO classification defines primary hepatic NEN (PHNEN) as a distinct entity. With only few cases of PHNEN reported and difficulty to discern them from hepatic metastases, evidence on optimal management is very limited.

Conference:

Presenting Author:

Authors: Apostolidis L, Kender Z, Flegka V, Winkler E, Krug S,

Keywords: hepatic NEN, liver NEN, PHNEN,

#3427 Updated morphological and immunohistochemical profile of neuroendocrine tumors developed in ovarian teratomas: A large series of a rare disease

Introduction: Ovarian carcinoid tumors are rare, often arising within a mature teratoma. No recent reevaluation of the immunophenotype of these tumors with new markers available has been performed.

Conference:

Presenting Author: Couvelard A

Authors: Leclerc J, Genestie C, Hentic O, Scoazec J, Couvelard A,

Keywords: NET, carcinoid, Ki67, ovarian teratoma, gynecology, pathology,

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#1189 European Information Network on Rare Cancers (RARECAREnet)

Introduction: NETs are considered as a rare cancer. Because of the complexity and the different disciplines involved, a multidisciplinary approach is desirable. The referral to centres of expertise (CoE) is indicated as the optimal strategy for effective management.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Van der Zwan J

Authors: Van der Zwan J, Trama A, Capoccacia R, Gatta G, Siesling S,

Keywords: Registry,